Development and prevalence of castration-resistant prostate cancer subtypes

BACKGROUND: Castration-resistant prostate cancer (CRPC) occurs when prostate cancer (CaP) progresses under therapy-induced castrate conditions. Several mechanisms have been proposed to explain this acquired resistance, many of which are driven by androgen receptor (AR). Recent findings, however, sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Vellky, Jordan E., Ricke, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522286/
https://www.ncbi.nlm.nih.gov/pubmed/32980775
http://dx.doi.org/10.1016/j.neo.2020.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522286/
https://www.ncbi.nlm.nih.gov/pubmed/32980775
http://dx.doi.org/10.1016/j.neo.2020.09.002

Ejemplares similares